DelveInsight’s “Keratoconus Pipeline Insight 2025” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in the Keratoconus pipeline landscape. It covers the Keratoconus Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Keratoconus Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Keratoconus Pipeline? Click here to explore the therapies and trials making headlines @ Keratoconus Pipeline Outlook Report

Key Takeaways from the Keratoconus Pipeline Report

• In July 2025, Price Vision Group announced a study objective is to compare accelerated and standard corneal crosslinking for treatment of progressive keratoconus or corneal ectasia.
• DelveInsight’s Keratoconus Pipeline report depicts a robust space with 3+ active players working to develop 3+ pipeline therapies for Keratoconus treatment.
• The leading Keratoconus Companies such as Epion Therapeutics Inc., iVeena Delivery Systems and others.
• Promising Keratoconus Therapies such as Riboflavin 5′-Phosphate, IVMED-80, Riboflavin, Dextenza, Prednisolone Acetate and others.

Want to know which companies are leading innovation in Keratoconus? Dive into the full pipeline insights @ Keratoconus Clinical Trials Assessment

The Keratoconus Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Keratoconus Pipeline Report also highlights the unmet needs with respect to the Keratoconus.

Keratoconus Overview

Keratoconus is an eye (ocular) disorder characterized by progressive thinning and changes in the shape of the cornea. The cornea is the thin, clear outer layer of the eye and is normally dome-shaped. Slowly progressive thinning of the cornea causes a cone-shaped bulge to develop towards the center of the cornea in the areas of greatest thinning. Affected individuals develop blurry or distorted vision, sensitivity to light (photophobia), and additional vision problems. Keratoconus often begins at puberty and most often is seen in teenagers or young adults. The specific underlying cause is not fully understood and most likely the condition results from the interaction of multiple factors including genetic and environmental ones.

Keratoconus Emerging Drugs Profile

• EpiSmart: Epion Therapeutics, Inc.

Epion has developed a drug, drug delivery device that fully optimize cross-linking and allow for the minimally-invasive treatment for corneal ectasias, including keratoconus. Unlike current treatments for keratoconus, EpiSmart is designed to be implemented upon initial diagnosis and can prevent disease progression. Epion’s elegant approach elevates the current standard of care for keratoconus by enabling the treatment of both eyes simultaneously and eliminating the need for further deterioration. EpiSmart is an investigational drug-device combination product. EpiSmart and its components (Epiprep, Ribostat, and UVA Device) are not yet approved by the Food and Drug administration or by other regulatory bodies. Currently, the drug is in Phase III stage of its development for the treatment of Keratoconus.

• IVMED-80: iVeena Delivery Systems

IVMED-80 is a proprietary non-surgical, non-invasive, disease modifying intervention with FDA orphan designation that upregulates lysyl oxidase (LOX) and induces corneal crosslinking pharmacologically. Upon issuance, the patent will provide US protection until at least 2041. The patent will protect key compositions and formulations of IVMED-80. In November 2020, the drug candidate received a $1.68 M in Federal government grants for its keratoconus developmental program. Currently the drug is in Phase II stage of development for the treatment of Keratoconus.

If you’re tracking ongoing Keratoconus Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Keratoconus Treatment Drugs

The Keratoconus Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of Keratoconus with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Keratoconus Treatment.
• Keratoconus Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Keratoconus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Keratoconus market.

Keratoconus Companies

Epion Therapeutics Inc., iVeena Delivery Systems and others.

Keratoconus Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical.

Keratoconus Products have been categorized under various Molecule types such as,

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

From emerging drug candidates to competitive intelligence, the Keratoconus Pipeline Report covers it all – check it out now @ Keratoconus Market Drivers and Barriers, and Future Perspectives

Scope of the Keratoconus Pipeline Report

• Coverage- Global
• Keratoconus Companies- Epion Therapeutics Inc., iVeena Delivery Systems and others.
• Keratoconus Therapies- Riboflavin 5′-Phosphate, IVMED-80, Riboflavin, Dextenza, Prednisolone Acetate and others.
• Keratoconus Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Keratoconus Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research – discover what’s next for the Keratoconus Treatment landscape in this detailed analysis @ Keratoconus Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Keratoconus: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Keratoconus – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Keratoconus Collaboration Deals
9. Late Stage Products (Phase III)
10. EpiSmart: Epion Therapeutics, Inc.
11. Mid Stage Products (Phase II)
12. IVMED-80: iVeena Delivery Systems
13. Drug profiles in the detailed report…..
14. Early Stage Products (Phase I)
15. Drug Name- Company name
16. Drug profiles in the detailed report…..
17. Pre-clinical and Discovery Stage Products
18. Drug Name- Company name
19. Drug profiles in the detailed report…..
20. Inactive Products
21. Keratoconus Key Companies
22. Keratoconus Key Products
23. Keratoconus- Unmet Needs
24. Keratoconus- Market Drivers and Barriers
25. Keratoconus- Future Perspectives and Conclusion
26. Keratoconus Analyst Views
27. Keratoconus Key Companies
28. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/keratoconus-pipeline-insight